947275-34-5

Basic information

• Product Name: (S)-1-Boc-4-benzyl-2-(hydroxymethyl)piperazine
• Synonyms: (S)-1-Boc-4-benzyl-2-(hydroxymethyl)piperazine;tert-Butyl (2S)-4-benzyl-2-(hydroxymethyl)piperazine-1-carboxylate
• CAS NO: 947275-34-5
• Molecular Formula: C17H26N2O3
• Molecular Weight: 306.39994
• Mol File: 947275-34-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 401.6 °C at 760 mmHg
• Flash Point: 196.7 °C
• Appearance: /
• Density: 1.123 g/cm³
• Vapor Pressure: 3.59E-07mmHg at 25°C
• Refractive Index: 1.541
• CAS DataBase Reference: (S)-1-Boc-4-benzyl-2-(hydroxymethyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-Boc-4-benzyl-2-(hydroxymethyl)piperazine(947275-34-5)
• EPA Substance Registry System: (S)-1-Boc-4-benzyl-2-(hydroxymethyl)piperazine(947275-34-5)

Safety Data

• Hazardous Substances Data: 947275-34-5(Hazardous Substances Data)

Usage

General Description

(S)-1-Boc-4-benzyl-2-(hydroxymethyl)piperazine is a chemical compound that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is a piperazine derivative with a benzyl and Boc (tert-butoxycarbonyl) protecting group, as well as a hydroxymethyl functional group. (S)-1-Boc-4-benzyl-2-(hydroxymethyl)piperazine has been found to exhibit significant potential in the treatment of various diseases, including cancer and neurological disorders. Its versatility and reactivity make it an important building block for the production of biologically active molecules, making it a valuable tool for researchers in drug discovery and development.

InChI:InChI=1/C17H26N2O3/c1-17(2,3)22-16(21)19-10-9-18(12-15(19)13-20)11-14-7-5-4-6-8-14/h4-8,15,20H,9-13H2,1-3H3/t15-/m0/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 85817-34-1 4-(phenylmethyl)-2-piperazinemethanol 
• 1214057-04-1 4-benzyl-piperazine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 149715-45-7 (S)-4-(phenylmethyl)-2-piperazinemethanol 
• 100-46-9 benzylamine 
• 366003-57-8 (+)-(2S)-methyl 2-(2-chloroacetylamino)-3-hydroxypropanoate 
• 149648-97-5 (S)-3-(hydroxymethyl)-1-(phenylmethyl)-2,5-piperazinedione 
• 149715-46-8 (R)-4-(phenylmethyl)-2-piperazinemethanol 
• 1030377-21-9 (S)-2-(hydroxymethyl)piperazine-1-carboxylic acid tert-butyl ester 
• 100-52-7 benzaldehyde 
• 50-00-0 formaldehyd 
• 57260-70-5 4-benzyl-piperazine-1-carboxylic acid tert-butyl ester 
• 1214196-85-6 1-(tert-butoxycarbonyl)piperazine-2-carboxylic acid 
• 100-39-0 benzyl bromide 

Downstream Products

• 1380336-22-0 N¹-(((R)-4-benzylpiperazin-2-yl)methyl)-N¹-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine 
• 1380336-23-1 N¹-(((S)-4-benzylpiperazin-2-yl)methyl)-N¹-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine 
• 930783-25-8 (S)-hexahydropyrazino[2,1-c][1,4]oxazin-4(3H)-one 

Relevant articles and documents

Fluorine-substituted bimolecular carbazole derivative as well as preparation method and application thereof

The invention discloses a fluorine-substituted bimolecular carbazole derivative represented by a formula (I) or pharmaceutically acceptable salt thereof. R1, R2, R3, R4 and R5 are defined in the specification. The fluorine-substituted bimolecular carbazole derivative or the pharmaceutically acceptable salt thereof provided by the invention can be used for preparing a DNA methyltransferase inhibitor or a histone demethylase inhibitor, and in-vitro cancer cell anti-proliferation tests prove that the fluorine-substituted bimolecular carbazole derivative has anti-proliferation activity on cancer cells.

COMPOUNDS THAT INHIBIT MCL-1 PROTEIN

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (I), or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

General Procedures for the Lithiation/Trapping of N-Boc Piperazines

To provide α-substituted piperazines for early stage medicinal chemistry studies, a simple, general synthetic approach is required. Here, we report the development of two general and simple procedures for the racemic lithiation/trapping of N-Boc piperazin